MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG: 0853), has announced a forecast for its 2023 financial performance along with key business updates. The company anticipates generating sales within the range of RMB 330 million to RMB 340 million for the year, reflecting a substantial increase of 31% to 36% year-on-year.
This growth is attributed to the ongoing expansion of hospital access for its transcatheter aortic valve implantation (TAVI) product in China, resulting in an increased implantation volume and sales. Over the period, the TAVI products were introduced to 117 hospitals in China, marking a 27% year-on-year increase, with the implantation volume soaring by 45% year-on-year. Internationally, the products have penetrated nearly 100 hospitals across Argentina, Colombia, Thailand, and Russia as of December 31, 2023, with the number of overseas commercial implantation cases reaching 120, representing a 90% year-on-year surge.
The company’s third-generation TAVI product, VitaFlow III, has been submitted for marketing approval in China. Additionally, transcatheter mitral valve replacement products have been utilized in 10 compassionate use cases, and the left atrial appendage occluder product, AnchorMan, has received marketing approval both domestically and in local regions.
These developments underscore MicroPort CardioFlow’s commitment to innovation and expansion within the cardiovascular device market, both domestically and internationally.- Flcube.com
